[HTML][HTML] Immune-checkpoint inhibitors: long-term implications of toxicity
The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
[HTML][HTML] Kinase drug discovery 20 years after imatinib: progress and future directions
Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
[HTML][HTML] Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a …
JS Weber, MS Carlino, A Khattak, T Meniawy… - The Lancet, 2024 - thelancet.com
Background Checkpoint inhibitors are standard adjuvant treatment for stage IIB–IV resected
melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 …
melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 …
Recent advances in the treatment of melanoma
BD Curti, MB Faries - New England Journal of Medicine, 2021 - Mass Medical Soc
Advances in Melanoma Treatment The incidence of melanoma has increased, but mortality
has declined with improved management. Sentinel-node sampling has reduced morbidity …
has declined with improved management. Sentinel-node sampling has reduced morbidity …
Drug-tolerant persister cells in cancer: the cutting edges and future directions
Y Pu, L Li, H Peng, L Liu, D Heymann… - Nature Reviews …, 2023 - nature.com
Drug-tolerant persister (DTP) cell populations were originally discovered in antibiotic-
resistant bacterial biofilms. Similar populations with comparable features have since been …
resistant bacterial biofilms. Similar populations with comparable features have since been …
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final …
E Livingstone, L Zimmer, JC Hassel, M Fluck… - The Lancet, 2022 - thelancet.com
Background The IMMUNED trial previously showed significant improvements in recurrence-
free survival for adjuvant nivolumab plus ipilimumab as well as for adjuvant nivolumab alone …
free survival for adjuvant nivolumab plus ipilimumab as well as for adjuvant nivolumab alone …
Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma
AMM Eggermont, M Kicinski, CU Blank… - NEJM …, 2022 - evidence.nejm.org
Background In the previously reported primary analyses of this phase 3 trial, 12 months of
adjuvant pembrolizumab resulted in significantly longer recurrence-and distant metastasis …
adjuvant pembrolizumab resulted in significantly longer recurrence-and distant metastasis …
Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma
I Fraterman, ILM Reijers, P Dimitriadis, A Broeks… - Nature Medicine, 2023 - nature.com
Neoadjuvant immune checkpoint blockade (ICB) outperforms adjuvant ICB for treatment of
stage IIIB–D melanoma, but potential biomarkers of response, such as interferon-gamma …
stage IIIB–D melanoma, but potential biomarkers of response, such as interferon-gamma …
[HTML][HTML] Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II …
No prospective data were available prior to 2021 to inform selection between combination
BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) …
BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) …